Skip to main content
Premium Trial:

Request an Annual Quote

Genomic Health Says Strong Oncotype DX Sales Help Boost Q3 Revenue 124 Percent

NEW YORK (GenomeWeb News) - Genomic Health yesterday said third-quarter revenues bolted 124 percent, R&D spending surged 75 percent, and net loss fell by 11 percent.
Total receipts for the three months ended Sept. 30 increased to $15.9 million from $7.1 million year over year.
Product revenues from Oncotype Dx jumped 129 percent to $15.8 million from $6.9 million, while contract revenue slid 40 percent to $120,000.
Genomic Health CEO Randy Scott, said the recent inclusion of Oncotype DX, its diagnostic for breast cancer recurrence, in the guidelines the American Society of Clinical Oncology shows that the test “is becoming standard practice in breast cancer treatment planning.”
As GenomeWeb Daily News reported last week, ASCO “recommends using the test” and “differentiated it as an optimal tool for breast cancer treatment selection," said Genomic Health’s chief medical officer Steve Shak.
Third-quarter R&D spending increased to $5.6 million from $3.2 million in the year-ago period.
Net loss for the quarter was narrowed to $7.3 million from $8.2 million.
Genomic Health said it had around $26.8 million in cash and equivalents, and $47 million in short-term investments as of Sept. 30.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.